Trades and observations from a British contrarian stock investor

This blog is not intended to give financial advice. Before investing, do your own research and consult your financial adviser if appropriate. The accuracy of any information included is not guaranteed and may be subject to conjecture or interpretation by Contrarian Investor. Therefore visitors should validate all facts using alternative sources where possible.

Wednesday, February 3, 2010

Doubts about Recentin and ex dividend hits Astra Zeneca

Astra Zeneca (AZN) was down over 3% this morning to £28.32 as concerns about whether its bowel cancer drug, Recentin (cediranib) in a head to head phase III clinical against Roche's Avastin would be positive when results are released in the first half of 2010 (Horizon III trial). The stock also went ex-dividend today. Recentin failed a final stage clinical in lung cancer in 2008 and focus is now on colo-rectal cancer.

Contrarian Investor believes a good entry point for AZN would be around the £25 mark.
Posted by Contrarian Investor UK at 11:42 AM
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)